Cognition Therapeutics secured a 20-year US patent for a polymorphic crystalline formulation of Zervimesine (CT1812), a lead candidate targeting Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy. The patent protection extends through 2045, with potential extension to 2050, covering composition, manufacturing process, and therapeutic applications for age-related neurodegeneration.
Key Points
- Patent covers polymorphic form with improved chemical and thermodynamic stability
- Protection extends through 2045, potentially 2050 with standard extension
- Zervimesine in Phase 2 trials for cognitive and neurodegenerative disorders
Longevity Analysis
This patent milestone represents substantive progress in pharmacological intervention for cognitive decline and neurodegenerative disease. The improved pharmaceutical profile of the crystalline form addresses a fundamental barrier to drug efficacy—bioavailability and stability—which directly impacts the nervous system's capacity to maintain cognitive function and resist age-related deterioration. Patent protection through 2050 signals commercial viability and sustained development momentum, increasing the likelihood that this approach will reach clinical availability during the decade when cognitive preservation becomes increasingly critical for population health outcomes.
Original published by Longevity.Technology.